Other News

MicroVention® Announces FDA Approval For Neuro Stent Device

ALISO VIEJO, Calif., May 31, 2018 /PRNewswire/ — MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Premarket Approval (PMA) for the LVIS® and LVIS® Jr. stents for stent-assisted coil embolization of intracranial aneurysms. The LVIS® and LVIS® Jr. stents are the first and only stents PMA approved for […]

Keystone Heart Ltd Announces First Enrollment in REFLECT Phase II incorporating TriGUARD 3™ Cerebral Embolic Protection device

CAESAREA, Israel and TAMPA, Fla., May 31, 2018 /PRNewswire/ — Keystone Heart Ltd., the leading medical device company focused on providing complete cerebral protection for patients undergoing cardiac procedures, today announced the launch of Phase II of the REFLECT trial to evaluate the safety and efficacy of the next generation of Keystone Heart […]

JC Medical Announces First-in-Human Treatment with the Unique Transfemoral J-Valve TAVI Device for Aortic Regurgitation

BURLINGAME, Calif.–(BUSINESS WIRE)– JC Medical, Inc. announced the treatment of the first patient with the company’s Transfemoral TAVI device, the J-Valve TF System for aortic regurgitation. The first patient was treated at St. Paul’s Hospital – Vancouver, Canada by John Webb, MD, FACC, FSCAI, Director of Interventional Cardiology. There are currently […]

Teleflex to Present at the 39th Annual Goldman Sachs Global Healthcare Conference

WAYNE, Pa.–(BUSINESS WIRE)–Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 39th Annual Goldman Sachs Global Healthcare Conference at the Terranea Resort, Rancho Palos Verdes, California, on Wednesday, June 13, 2018 at 2:40 p.m. (PT). A live audio webcast of the […]

Espero BioPharma to Present at the 2018 BIO International Convention, Wednesday, June 6, 2018

JACKSONVILLE, Fla., May 30, 2018 (GLOBE NEWSWIRE) — Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Quang Pham, Espero’s Chief Executive Officer, will present at the 2018 BIO International Convention at 2:00 PM ET […]

Avinger Announces Presentations and Posters Featuring Lumivascular Technology at New Cardiovascular Horizons Annual Conference

REDWOOD CITY, Calif., May 30, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions and posters highlighting the company’s Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference taking place this week in New […]

InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS

TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) —  InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS),  thrombus management technologies and neurovascular devices, today announced that Professor Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, presented the expanded 24 month […]

TARA Biosystems’ CEO Misti Ushio Named to Fast Company’s Top 100 Most Creative People in Business

NEW YORK, May 30, 2018 /PRNewswire/ — TARA Biosystems Inc., a company offering physiologically relevant, human “heart-on-a-chip” tissue-models for drug discovery and development applications, is proud to announce that TARA CEO Dr. Misti Ushio has been recognized by Fast Company as one of the Top 100 Most Creative People in Business today. The annual list honors an […]

Ancora Heart Announces $17.8 Million Financing for First-of-Its-Kind Therapy for Systolic Heart Failure

SANTA CLARA, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced the closing of an initial tranche of $17.8 million in a financing round expected to reach $30 million, led by Savitr Capital and other existing investors. Ancora Heart’s AccuCinch® Ventricular Repair System is […]

ALVIMEDICA UNVEILS THE DIAB8 RANDOMIZED STUDY, THE FIRST AND ONLY DIABETIC DES RANDOMIZED TRIAL DESIGNED FOR SUPERIORITY

• Diab8 is a 55-center, 3.040-patient randomized controlled trial that pits the performance of Cre8™ EVO, a Polymer-free Amphilimus-eluting stent, against the Everolimus-Eluting stents in the treatment of coronary artery disease in diabetic patients • The Diab8 study is designed to establish the superior efficacy of the Cre8™ EVO, the […]